Clindamycine [Inn-French]

Clindamycine [Inn-French] Brand names, Clindamycine [Inn-French] Analogs

Clindamycine [Inn-French] Brand Names Mixture

No information avaliable

Clindamycine [Inn-French] Chemical_Formula

C₁₈H₃₃ClN₂O₅S

Clindamycine [Inn-French] RX_link

http://www.rxlist.com/cgi/generic2/clindam.htm

Clindamycine [Inn-French] fda sheet

Clindamycine_[Inn-French] FDA

Clindamycine [Inn-French] msds (material safety sheet)

Clindamycine [Inn-French] Synthesis Reference

Birkenmeyer, U.S. Pat. 3,475,407(1970)

Clindamycine [Inn-French] Molecular Weight

424.984 g/mol

Clindamycine [Inn-French] Melting Point

255 ^oC

Clindamycine [Inn-French] H₂O Solubility

30.6 mg/L

Clindamycine [Inn-French] State

Solid

Clindamycine [Inn-French] LogP

1.224

Clindamycine [Inn-French] Dosage Forms

Capsules; Intramuscular solution; Intravenousparenteral solution; Topical solution; Topical lotion; Topical gel; Vaginal cream; Vaginal ovules

Clindamycine [Inn-French] Indication

For the treatment of serious infections caused by susceptible anaerobic bacteria (anaerobes, streptococci, pneumococci, and staphylococci)

Clindamycine [Inn-French] Pharmacology

Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.

Clindamycine [Inn-French] Absorption

- 90% - oral

Clindamycine [Inn-French] side effects and Toxicity

Orally and parenterally administered clindamycin has been associated with severe colitis (pseudomembranous colitis) which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Clindamycine [Inn-French] Patient Information

Clindamycine [Inn-French] Organisms Affected

Enteric bacteria and other eubacteria